JOURNAL ARTICLE
RESEARCH SUPPORT, N.I.H., EXTRAMURAL
REVIEW
Add like
Add dislike
Add to saved papers

Postprandial hyperglycemia and cardiovascular disease.

Endocrine Practice 2006 January
OBJECTIVE: To review the role of postprandial hyperglycemia in the development of type 2 diabetes mellitus and cardiovascular disease.

METHODS: The pathogenic mechanisms involved in the deterioration of glucose tolerance are discussed, and findings from relevant epidemiologic and clinical interventional studies are presented.

RESULTS: It is now well established that hyperglycemia is an independent risk factor for cardiovascular disease, with no apparent threshold. In clinical practice, glycemic exposure is measured by hemoglobin A1c levels. These values reflect the contribution of fasting and postprandial plasma glucose levels during the previous 2 to 3 months. Epidemiologic studies have indicated that, at hemoglobin A1c levels (5.5%) already associated with a substantially increased risk for cardiovascular mortality, fasting plasma glucose levels are generally normal. These observations implicate isolated postprandial hyperglycemia as a cardiovascular risk factor. Controlled interventional clinical trials have found that reduction of postprandial hyperglycemia decreases cardiovascular events or surrogates thereof.

CONCLUSION: Postprandial hyperglycemia should be considered a cardiovascular risk factor similar to hypertension, hyperlipidemia, and smoking; accordingly, it should be monitored and treated.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app